ARROWHEAD PHARMACEUTICALS IN (ARWR) Institutional Selling Activity

Several institutional investors tracked by InsiderSet reduced exposure to ARROWHEAD PHARMACEUTICALS IN (ARWR) during the quarter ended June 30, 2026 based on sequential SEC Form 13F filings.

The largest disclosed institutional seller of ARWR during the latest reporting period reduced its reported position by approximately $28,167.616 based on quarter-end filing values.

Institutional selling activity may reflect profit-taking, sector rotation, portfolio rebalancing, or changing conviction levels among major investment firms. InsiderSet tracks quarter-over-quarter holding reductions, full exits, estimated value changes, and historical selling activity using publicly disclosed SEC filing data.

The investors covered on this page collectively reduced approximately $76,193.948 in reported ARWR exposure during the latest filing period, although many institutional holders continue to maintain significant long-term ownership positions in ARROWHEAD PHARMACEUTICALS IN.

Portfolio quarterNameTypeQuantityRemainingReported stock balance
Q1 2026Sequoia Financial AdvisorsSell-363,602$225,846
Q4 2023Renaissance Technologies LLCSell-259,500122,000$3,733
Q3 2023Renaissance Technologies LLCSell-3,400381,500$10,251
Q1 2023Renaissance Technologies LLCSell-201,000292,800$7,437
Q4 2022Renaissance Technologies LLCSell-261,600493,800$20,029
Q3 2021Renaissance Technologies LLCSell-125,10054,100$3,377
Q2 2021Renaissance Technologies LLCSell-62,400179,200$14,841
Q1 2021Renaissance Technologies LLCSell-424,800241,600$16,020
Q1 2020Renaissance Technologies LLCSell-55,900666,400$19,172
Q3 2019Renaissance Technologies LLCSell-131,200657,600$18,531
Q1 2019Renaissance Technologies LLCSell-203,764170,400$3,127

Frequently asked questions about ARWR activity

  • Which institutional owners are buying ARWR?

    Institutional owners buying ARWR include investors who have either initiated new positions or increased their existing holdings based on recent SEC 13F filings. The activity table above highlights which funds added shares in the latest reporting periods and how their positions changed over time.

  • What does "buy" mean in ARWR activity?

    "Buy" means an investor increased their reported position in ARWR compared to the prior reporting period. This reflects growing exposure to ARROWHEAD PHARMACEUTICALS IN (ARWR) rather than necessarily a brand-new position (though new positions also appear as buys when prior quantity was zero).

  • Is institutional interest in ARWR increasing?

    Institutional interest in ARWR can be assessed by comparing the number of tracked funds adding or increasing positions versus those trimming or exiting across the periods shown. A higher number of additions typically signals increasing participation among large filers, but it should be read alongside position sizes and the full table.